


# Applications of Machine Learning for Clinical Practice



Geert Litjens  
Department of Pathology  
Radboud University Medical Center

# The promise of digital pathology?

## 5 Key criteria for evaluating Digital Pathology

The adoption of digital pathology is evolving and offers functionality that goes far beyond the microscope. These new opportunities significantly increase workflow efficiency. They move time-consuming tasks to the computer and allow the pathologist to spend more time on reviewing cases. Here are five key criteria when evaluating a solution for digital pathology.

**1 Optimized workflow**

- Access to all relevant patient data in one workstation.
- Minimum mouse mileage and clicks through seamless integration of control and interface.
- High-speed image display through web technology and server-side rendering.
- Improved ergonomics, avoiding shoulder and neck problems.

**2 Collaboration with other specialists**

- Easily share information across department boundaries.
- Tailored dynamic worklists and support for multidisciplinary team meetings.
- Sharing of workload and second opinions.
- Strategy towards integrated diagnostics.

**3 Availability anytime, anywhere**

- View, present and discuss from any workstation.
- Vendor-Neutral Archive (VNA) for centralized storage.
- Scalable to handle growth of users and production.

**4 More consistent reviews**

- Automated image analysis for frequent cases.
- Support for counting and percentage calculations.
- Teaching functionality with easy tag and search.
- Compare with patient history data.


**5 Integration with healthcare IT solutions**

- Support for standards like HL7 and DICOM to integrate with EMRs, LIS, etc.
- Vendor agnostic approach.
- Part of the full enterprise image management strategy.


© 2015 Sectra AB




# The promise of digital pathology?



# The promise of digital pathology?



# The promise of digital pathology?



---

# The promise of digital pathology?



Scanners




Storage



Computers




# The promise of digital pathology?



Multiple focal points




Large slides




Oil immersion

---


# The promise of digital pathology?







---

# Computational Pathology




# Machine learning



---

# ML: a bit of history



# nature

THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE

At last — a computer program that  
can beat a champion Go player **PAGE 484**

## ALL SYSTEMS GO

CONSERVATION

### SONGBIRDS À LA CARTE

*Illegal harvest of millions  
of Mediterranean birds*

**PAGE 452**

RESEARCH ETHICS

### SAFEGUARD TRANSPARENCY

*Don't let openness backfire  
on individuals*

**PAGE 459**

POPULAR SCIENCE

### WHEN GENES GOT 'SELFISH'

*Darwin's 'selfish'  
card forty years on*

**PAGE 462**

NATURE.COM/NATURE

26 January 2015 £10


Vol. 529, No. 7581



# ML: a bit of history




30 possible moves per turn  
40 turns per game



250 possible moves per turn  
150 turns per game

---

# How to build an ML system?




Normal lymph node


Breast cancer metastasis

# How to build an ML system?


Examples



Features




Classification




---

# How to build an ML system?




Normal lymph node



Breast cancer metastasis

# SOON WE WON'T PROGRAM COMPUTERS. WE'LL TRAIN THEM LIKE DOGS



EDWARD C. MONAGHAN

## SHARE



SHARE  
13183



TWEET

BEFORE THE INVENTION of the computer, most experimental psychologists thought the brain was an unknowable black box. You could analyze a subject's behavior—*ring bell, dog salivates*—but thoughts, memories, emotions? That stuff was obscure and inscrutable, beyond the reach of science. So these behaviorists, as they called themselves, confined their work to the study of stimulus and response, feedback and reinforcement: bells and saliva. They gave up trying to

## MOST POPULAR



**BUSINESS**  
SpaceX's President is Thinking Even Bigger Than Elon Musk  
ERIN GRIFFITH

TRANSPORTATION



[JASON TANZ](#) IDEAS 05.17.16 06:50 AM

**SOON WE WON'T PROGRAM COMPUTERS. WE'LL  
TRAIN THEM LIKE DOGS**

---

# How to build an ML system?





---

# Practical applications of computation pathology

Detection of  
metastases in lymph  
nodes


Automatic mitotic  
counts

Tumor  
qua

---

# Detection of metastases in lymph nodes






H&E



IHC



pN+


pNo

+


+

-

-




H&E



IHC

# Detection of metastases in lymph nodes



---

# Breast cancer metastasis detection



---

# Data

Centrum	Number of slides
CWZ (Nijmegen)	200
LabPON (Hengelo)	200
Rijnstate (Arnhem)	200
Radboudumc (Nijmegen)	439
UMCU (Utrecht)	350
<b>Total</b>	<b>1399</b>



# CAMELYON16



# CAMELYON17


---

# Why challenges?



Great way to collect and compare solutions for a problem

Fair comparison of algorithms

- Same evaluation metric
- Same ground truth definition
- Same training and test datasets

Rank ▲	Team ◇	AUC ◇	Description ◇
01	Harvard Medical School (BIDMC) and Massachusetts Institute of Technology (CSAIL), USA	0.9250	  
02	ExB Research and Development co., Germany	0.9173	  
03	Independent participant, Germany	0.8680	  
04	Health Sciences Middle East Technical University, Turkey	0.8669	  
05	NLP LOGIX co., USA	0.8332	  
06	University of Toronto, Electrical and Computer Engineering, Canada	0.8181	  
07	The Warwick-QU Team, United Kingdom	0.7999	  
08	Radboud University Medical Center, Diagnostic Image Analysis Group, Netherlands	0.7828	  
09	HTW-BERLIN, Germany	0.7717	 
10	University of Toronto, Electrical and Computer Engineering, Canada	0.7666	  

# Comparing to pathologists



Pathologist


HMS & MIT

Radboudumc

Exb

METU

NLP LOGIX



Pathologist


HMS & MIT

Radboudumc

Exb

METU

NLP LOGIX



Pathologist


HMS & MIT


Radboudumc

Exb


METU

NLP LOGIX





# Implemented in clinical practice



---



# Practical applications of computation pathology


Detection of  
metastases in lymph  
nodes


Automatic mitotic  
counts


Tumor  
qua

# Automatic mitotic counts









# Automatic mitotic counts




## Assessment of Mitosis Detection Algorithms 2013

AMIDA13 | MICCAI Grand Challenge

D. C. Cireşan, A. Giusti, L. M. Gambardella, and J. Schmidhuber, "Mitosis detection in breast cancer histology images with deep neural networks," in *International Conference on Medical Image Computing and Computer-assisted Intervention*. Springer, 2013, pp. 411–418.

M. Veta, P. J. van Diest, M. Jiwa, S. Al-Janabi, and J. P. Pluim, "Mitosis counting in breast cancer: Object-level interobserver agreement and comparison to an automatic method," *PloS one*, vol. 11, no. 8, p. e0161286, 2016.



## Tumor Proliferation Assessment Challenge 2016


TUPAC16 | MICCAI Grand Challenge

E. Zerhouni, D. Lányi, M. Viana, and M. Gabrani, "Wide residual networks for mitosis detection," in *Biomedical Imaging (ISBI 2017), 2017 IEEE 14th International Symposium on*. IEEE, 2017, pp. 924–928.



K. Paeng, S. Hwang, S. Park, M. Kim, and S. Kim, "A unified framework for tumor proliferation score prediction in breast histopathology," *arXiv preprint arXiv:1612.07180*, 2016.


---


# Challenge 1: Reference standard




# IHC offers a solution








# Challenge 2: staining differences




TNBC dataset


TUPAC dataset

## Solution 2: Data augmentation







**Mitotic detections**




**Mitosis density**





56 mitoses




Direct visibility of hotspots



38 mitoses




# Challenge 2: staining differences




TNBC dataset

TUPAC dataset


# 'Traditional' stain normalization



- Only modifies color information
- Very time-consuming algorithm
- Dependent on presence of nuclei
- Parameter tweaking for new datasets





# Stain normalization using cycleGANs




---

# Stain normalization using cycleGANs



# Stain normalization using cycleGANs



Experiment		Dice coefficient AMC			
Augmentations	Stain transformed	Mean	Std	Min	Max
x	x	0.36	0.21	0.09	0.65
x	✓	<b>0.85</b>	0.06	0.69	0.91
✓	x	0.78	0.08	0.65	0.87
✓	✓	<b>0.85</b>	0.05	0.72	0.91

---

# Practical applications of computation pathology

Detection of  
metastases in lymph  
nodes

Automatic mitotic  
counts

Tumor/stroma ratio  
quantification

Identific  
assoc

# Tumor/stroma ratio quantification

Annals of Oncology

original articles

*Annals of Oncology* 24: 179–185, 2013

doi:10.1093/annonc/mds246


Published online 2 August 2012


## **The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial**


A. Huijbers<sup>1</sup>, R. A. E. M. Tollenaar<sup>1</sup>, G. W. v Pelt<sup>1</sup>, E. C. M. Zeestraten<sup>1</sup>, S. Dutton<sup>3</sup>, C. C. McConkey<sup>6</sup>, E. Domingo<sup>7</sup>, V. T. H. B. M. Smit<sup>2</sup>, R. Midgley<sup>4</sup>, B. F. Warren<sup>8</sup>, E. C. Johnstone<sup>4</sup>, D. J. Kerr<sup>5</sup> & W. E. Mesker<sup>1\*</sup>


*Departments of <sup>1</sup>Surgery; <sup>2</sup>Pathology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; <sup>3</sup>Centre for Statistics in Medicine, University of Oxford, Oxford; Departments of <sup>4</sup>Oncology; <sup>5</sup>Clinical Pharmacology, University of Oxford, Oxford; <sup>6</sup>Clinical Trials Unit, University of Warwick, Coventry; <sup>7</sup>Molecular and Population Genetics, Wellcome Trust Center for Human Genetics, Oxford; <sup>8</sup>Department of Pathology, John Radcliffe Hospital, Headington, Oxford, UK*



*Received 28 February 2012; revised 15 June 2012; accepted 18 June 2012*











$$TSR = \frac{\text{Amount of stroma}}{\text{Amount of tumor} + \text{stroma}} = 72\%$$


---

# Tumor/stroma ratio quantification

125 patients with rectal carcinoma

- Stage I-III
- At least five year follow-up
- No neo-adjuvant therapy

# Tumor/stroma ratio quantification





# Tumor/stroma ratio quantification

Crosstab: Observer 1 versus Observer 2				
$\kappa = 0.548$		Observer 2		
		Stroma-low	Stroma-high	Total
Observer 1	Stroma-low	75	8	83
	Stroma-high	16	26	42
	Total	91	34	125

Crosstab: TSR-Visual (consensus) versus TSR-auto				
$\kappa = 0.518$		TSR-auto		
		Stroma-low	Stroma-high	Total
TSR-visual (consensus)	Stroma-low	60	27	87
	Stroma-high	3	35	38
	Total	63	62	125


# Tumor/stroma ratio quantification



# Tumor/stroma ratio quantification

**Table 5. Uni- and multivariate Cox regression analysis for disease-specific survival.**

	Univariate analysis		Multivariate analysis			
			Visual		Auto	
	HR (95% CI)	P-val.	HR (95% CI)	P-val.	HR (95% CI)	P-val.
Age	1.01 (0.98-1.04)	0.376				
Gender	0.85 (0.45-1.60)	0.604				
T-stage	2.42 (1.47-3.99)	<b>0.001</b>	1.97 (1.16-3.34)	<b>0.012</b>	2.05 (1.24-3.38)	<b>0.005</b>
N-stage	2.16 (1.49-3.14)	<b>0.0001</b>	2.06 (1.13-3.75)	<b>0.018</b>	2.12 (1.17-3.84)	<b>0.014</b>
Surgical procedure	1.48 (0.94-2.31)	0.090				
Tumour grade	2.96 (1.42-6.17)	<b>0.004</b>	2.40 (1.05-5.48)	<b>0.038</b>	2.23 (0.99-5.00)	0.052
Adj. <u>chemoth.</u>	1.17 (0.28-4.82)	0.831				
Adj. <u>radioth.</u>	2.56 (1.41-4.63)	<b>0.002</b>	0.72 (0.27-1.88)	0.496	0.68 (0.27-1.72)	0.417
TSR-visual	1.96 (1.08-3.58)	<b>0.027</b>	2.07 (1.09-3.93)	<b>0.026</b>		
TSR-auto	2.57 (1.36-4.86)	<b>0.004</b>			2.75 (1.44-5.27)	<b>0.002</b>



---

# Practical applications of computation pathology



Automatic mitotic  
counts

Tumor/stroma ratio  
quantification

Identification of tumor  
associated stroma

Predict  
ex


# Prognosis of in-situ lesions




Diagnosis	Entire dataset			Training dataset			Testing dataset		
	# Patient	# WSI	%	# Patient	# WSI	%	# Patient	# WSI	%
Benign	321	675	36.4	209	437	37.9	112	238	33.9
Proliferative	312	937	35.4	209	608	37.9	103	329	32.3
Proliferative with atypia	57	212	6.5	42	171	7.6	15	41	4.5
Ductal carcinoma in-situ	58	222	6.6	—	—	—	58	222	17.6
Lobular carcinoma in-situ	10	29	1.1	7	21	1.2	3	8	0.9
Invasive breast cancer	124	312	14.0	85	222	15.4	39	90	11.8
Total	882	2387	100	552	1459	100	330	928	100

# Tumor-associated stroma


Tumor stroma identification pipeline




input WSI




CNN I - tissue component classifier








classification map









CNN II - stroma classifier





probability map for





# Tumor-associated stroma



---

# Practical applications of computation pathology


Tumor/stroma ratio  
quantification

Identification of tumor  
associated stroma

Prediction of gene  
expression

Gleason  
prostate


# Prediction of gene expression



Mean RNA expression 11  
proliferation-associated genes

Score: 0.567

# Neural compression





---

# Prediction of gene expression

Team	Spearman's $\rho$
Lunit (mitosis counting)	0.617
Radboud (neural compression)	0.557
Radboud (regular CNN)	0.516
ContextVision	0.503

# Explainability of ML systems



---


# Practical applications of computation pathology

Identification of tumor  
associated stroma

Prediction of gene  
expression

Gleason grading of  
prostate cancer

# Prostate cancer segmentation



## Training set

150 slides

- 83 normal
- 67 cancer



## Test set

75 slides



- 30 normal
- 45 cancer

## Results

AUC of 0.99...




# Prostate cancer: epithelium segmentation




## 1) Training of IHC network



Input data: 25 IHC WSIs  
(20 training, 5 validation)




Specimens are stained with CK8/18 and P63 to mark epithelial tissue and basal cell layer.



Color deconvolution is applied to each slide. Only the channel representing the epithelial tissue is used, the rest is discarded.




Artifacts are introduced due to imperfections in the staining and color deconvolution method (Example: top left corner).




Artifacts are removed manually in selected regions. Training data is sampled from these regions.

### Network training



A 5-layer deep U-Net is trained on the corrected IHC regions. Areas with artifacts are sampled more.




The IHC network produces precise segmentation masks given an IHC slide, independent of the color deconvolution.

## 2) Training of H&E network




Input data: 62 restained and registered  
IHC/H&E pairs (50 training, 12 validation)




Slide pairs are registered on cell-level due to the use of restained slides and non-linear patch based registration.




The trained IHC network is applied to each IHC slide. The network output is used as the training mask for the H&E network. No additional post processing or manual annotations are used.



### Network training




A 6-layer deep U-Net is trained on H&E and the masks generated by the IHC network.



The trained H&E network segments epithelial tissue on H&E.

# Prostate cancer: epithelium




Regions	N	F1 score mean (min, max)	Accuracy	Jaccard
All regions	160	$0.893 \pm 0.05$ (0.661, 0.959)	0.940	0.811

Network	Evaluation	Accuracy	F1	Jaccard
Gertych <i>et al.</i> <sup>8</sup>	Cross-validation	—	—	$0.595 \pm 0.15$
Li <i>et al.</i> <sup>12</sup>	Cross-validation	—	—	0.737*
Our method	Hold-out validation	$0.866 \pm 0.07$	$0.835 \pm 0.13$	$0.735 \pm 0.16$

---

# Prostate cancer: Gleason Grading





---

# Prostate cancer: Gleason Grading

Collected prostate biopsies from 1271 patients

Grade	Training Set	Validation Set	Test Set
No cancer	777	200	271
3	1508	139	120
4	2102	138	134
5	329	42	100
Totals	4716	519	625







20% benign  
15% Gleason 4  
65% Gleason 5




Gleason 5+4

# Gleason Grading



Performance of model on GGG: acc 0.84, k 0.83

# Observer experiment



# The people who do all the work...

## Scientific staff



**Caner Mercan**  
Postdoctoral  
researcher



**David Tellez**  
PhD student



**Elke Luskamp-  
Huntink**  
Study manager



**Hans Pinckaers**  
PhD student



**Jasper Linmans**  
PhD student



**John-Melle  
Bokhorst**  
PhD student



**Mart van  
Rijthoven**  
PhD student



**Maschenka  
Balkenhol**  
Pathology resident  
and PhD student



**Meyke Hermesen**  
PhD student



**Oscar Geessink**  
PhD student



**Péter Bándi**  
PhD student



**Thomas de Bel**  
PhD student



**Wouter Bulten**  
PhD student



**Yiping Jiao**  
PhD student



**Zaneta  
Swiderska-  
Chadaj**  
Postdoctoral  
researcher

## Technical staff



**Karel Gerbrands**  
Research Software  
Engineer



**Maud Wekking**  
Research technician



**Merijn van Erp**  
Scientific  
programmer

## Visiting researchers




**Emiel Stoelinga**  
Master student




**Koen Dercksen**  
Master student



**Leander van  
Eekelen**  
Master student



**Michel Kok**  
Master student



**Patrick Sonsma**  
Master student


## Faculty



**Jeroen van der  
Laak**  
Associate  
professor/Group  
leader



**Geert Litjens**  
Assistant professor



**Francesco  
Ciompi**  
Assistant Professor



# Computational Pathology Group

The Computational Pathology Group develops, validates and deploys novel medical image analysis methods based on deep learning technology and focusing on computer-aided diagnosis. Application areas include diagnostics and prognostics of breast, prostate and colon cancer. We have rapidly expanded over the last few years, counting over 15 people today. Our group is among the international front runners in the field, witnessed for instance by our highly successful CAMELYON challenges. We have a strong translational focus, facilitated by our close collaboration with clinicians and industry.



Automated tumor detection

[computationalpathology.eu](https://computationalpathology.eu)

# Automating kidney diagnostics


- Glomerular counting
- *ct* score vs % Atrophic tubuli

## Quantitative criteria for tubular atrophy: *ct* score

ct0	No tubular atrophy
ct1	Tubular atrophy involving up to 25% of the area of cortical tubules (mild tubular atrophy)
ct2	Tubular atrophy involving up to 26-50% of the area of cortical tubules (moderate tubular atrophy)
ct3	Tubular atrophy involving in >50% of the area of cortical tubules (severe tubular atrophy)




# Automating kidney diagnostics





---

# Automating kidney diagnostics

- Applied to 15 WSIs of large tumor nephrectomies
- All glomeruli annotated
  - *1747 Glomeruli and 72 Sclerotic glomeruli*




# Automating kidney diagnostics



	TP	FP	FN
Glomeruli (n=1747)	93.4% (1632)	8.4 % (149)	6.6 % (115)
Sclerotic glomeruli (n=76)	76.4 % (55)	45.5 % (46)	23.6 % (17)
<b>Total (n=1819)</b>	<b>92.7 % (1687)</b>	<b>10.4 % (192)</b>	<b>7.3 % (132)</b>


# Automating kidney diagnostics




Inter-class correlation coefficient

	P1	P2	P3	CNN
P1		0.94	0.95	<b>0.78</b>
P2			0.95	<b>0.85</b>
P3				<b>0.85</b>
CNN				


# Automating kidney diagnostics



	No.
Pathologist 1	13
Pathologist 2	13
Pathologist 3	14
CNN <i>Glomeruli</i>	17
CNN <i>Sclerotic glomeruli</i>	1



# Automating kidney diagnostics



## Bonferroni analysis

	0	1	2	3
0		0.24	<0.001	<0.001
1			<0.001	<0.001
2				<0.01
3				

## Weighted kappa

	P1	P2	P3
P1		0.13	0.34
P2			0.20
P3			

## Quantitative criteria for tubular atrophy: ct score

ct0	No tubular atrophy
ct1	Tubular atrophy involving up to 25% of the area of cortical tubules (mild tubular atrophy)
ct2	Tubular atrophy involving up to 26-50% of the area of cortical tubules (moderate tubular atrophy)
ct3	Tubular atrophy involving in >50% of the area of cortical tubules (severe tubular atrophy)